This discovery that TDP‐43 represses cryptic exons offers a number of exciting possibilities for understanding the molecular underpinnings of ALS and FTD, leading to the development of sensitive new biomarkers and therapeutic targets. This evidence concerns the gene TARDBP and frontotemporal dementia.